EPHA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib inhibits tyrosine-kinases including cKIT and EPH, and is approved for the treatment of chronic myeloid leukemia and acute lymphatic leukemia [36, 37].